{
  "summary": {
    "total_tests": 204,
    "equivalent_results": 121,
    "different_results": 83,
    "high_significance_differences": 2,
    "medium_significance_differences": 0,
    "low_significance_differences": 0,
    "differences_by_focus": {
      "blast_thresholds": 12,
      "therapy_qualifiers": 1,
      "tp53_terminology": 6,
      "mds_blast_ranges": 18,
      "erythroid_handling": 8,
      "combination_scenarios": 2,
      "realistic_clinical_scenarios": 2,
      "age_dependent_differences": 10,
      "complex_cytogenetics": 2,
      "comutation_patterns": 4,
      "therapy_evolution": 2,
      "aml_vs_mds_borderline": 11,
      "disease_type_disagreement": 5
    },
    "differences_by_category": {
      "major_clinical_impact": 68,
      "significant_clinical_impact": 2,
      "terminology_only": 13
    }
  },
  "test_results": [
    {
      "test_id": "test_1_blast_thresholds",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.403931",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_2_blast_thresholds",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404015",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_3_blast_thresholds",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404066",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_4_blast_thresholds",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 but blasts <10 => cannot label AML here",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_category": "AML_GENETIC",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'npm1'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Favorable vs Unknown",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404120",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'npm1'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [
        "Risk category: Favorable vs Unknown",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_5_blast_thresholds",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404175",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_6_blast_thresholds",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 190,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404419",
      "significance": "critical",
      "clinical_impact_score": 190,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_7_blast_thresholds",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 160,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404491",
      "significance": "critical",
      "clinical_impact_score": 160,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_8_blast_thresholds",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404538",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_9_blast_thresholds",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404633",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_10_blast_thresholds",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 190,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404691",
      "significance": "critical",
      "clinical_impact_score": 190,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_11_blast_thresholds",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 160,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404752",
      "significance": "critical",
      "clinical_impact_score": 160,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_12_blast_thresholds",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404791",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_13_blast_thresholds",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404844",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_14_blast_thresholds",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 190,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404894",
      "significance": "critical",
      "clinical_impact_score": 190,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_15_blast_thresholds",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 160,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404942",
      "significance": "critical",
      "clinical_impact_score": 160,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": true
      }
    },
    {
      "test_id": "test_16_blast_thresholds",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.404980",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_17_blast_thresholds",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "significant_clinical_impact",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405027",
      "significance": "high",
      "clinical_impact_score": 70,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_18_blast_thresholds",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405069",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_19_blast_thresholds",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with BCR::ABL1 fusion",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405110",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_20_blast_thresholds",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405146",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_21_blast_thresholds",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "significant_clinical_impact",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405191",
      "significance": "high",
      "clinical_impact_score": 70,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_22_blast_thresholds",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: bZIP",
        "bZIP with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405229",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "bZIP": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_23_blast_thresholds",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with BCR::ABL1 fusion",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405267",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_24_blast_thresholds",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "blast_thresholds",
      "timestamp": "2025-06-06T22:51:57.405302",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {},
        "expected_difference": false
      }
    },
    {
      "test_id": "test_25_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405351",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      }
    },
    {
      "test_id": "test_26_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405400",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      }
    },
    {
      "test_id": "test_27_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405456",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "expected_difference": true
      }
    },
    {
      "test_id": "test_28_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
      "icc_classification": "AML with mutated NPM1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405512",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_29_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405565",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_30_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
      "icc_classification": "AML, NOS, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405621",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_31_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
      "icc_classification": "AML with mutated NPM1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405667",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_32_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405718",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_33_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
      "icc_classification": "AML, NOS, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405770",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_34_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
      "icc_classification": "AML with mutated NPM1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
        "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405816",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_35_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405866",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_36_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
      "icc_classification": "AML, NOS, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Any combination",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405918",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Any combination"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_37_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.405987",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_38_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406028",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_39_therapy_qualifiers",
      "input_data": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25.0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406068",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25.0,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "None"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_40_germline_qualifiers",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of Diamond-Blackfan anemia",
        "Qualifiers appended => AML with mutated NPM1, in the setting of Diamond-Blackfan anemia (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406120",
      "significance": "medium",
      "clinical_impact_score": 30,
      "clinical_consequences": [
        "Germline implications differ"
      ],
      "treatment_implications": [
        "Family screening recommendations differ",
        "Drug toxicity considerations differ"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "expected_difference": true
      }
    },
    {
      "test_id": "test_41_germline_qualifiers",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline BLM mutation"
        },
        "expected_difference": true
      },
      "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline BLM mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline BLM mutation",
        "Final classification => AML with NPM1 mutation, associated with germline BLM mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406169",
      "significance": "medium",
      "clinical_impact_score": 30,
      "clinical_consequences": [
        "Germline implications differ"
      ],
      "treatment_implications": [
        "Family screening recommendations differ",
        "Drug toxicity considerations differ"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline BLM mutation"
        },
        "expected_difference": true
      }
    },
    {
      "test_id": "test_42_germline_qualifiers",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline CEBPA mutation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation",
      "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline CEBPA mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline CEBPA mutation",
        "Final classification => AML with NPM1 mutation, associated with germline CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of germline CEBPA mutation",
        "Qualifiers appended => AML with mutated NPM1, in the setting of germline CEBPA mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406221",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline CEBPA mutation"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_43_germline_qualifiers",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
      "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => AML with NPM1 mutation, associated with germline DDX41 mutation",
        "Final classification => AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406272",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_44_germline_qualifiers",
      "input_data": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Fanconi anaemia"
        },
        "expected_difference": false
      },
      "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia",
      "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia",
      "who_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with Fanconi anaemia",
        "Classification with qualifiers => AML with NPM1 mutation, associated with Fanconi anaemia",
        "Final classification => AML with NPM1 mutation, associated with Fanconi anaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30.0",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "Qualifier => in the setting of Fanconi anaemia",
        "Qualifiers appended => AML with mutated NPM1, in the setting of Fanconi anaemia (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia",
        "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "germline_qualifiers",
      "timestamp": "2025-06-06T22:51:57.406323",
      "significance": "medium",
      "clinical_impact_score": 30,
      "clinical_consequences": [
        "Germline implications differ"
      ],
      "treatment_implications": [
        "Family screening recommendations differ",
        "Drug toxicity considerations differ"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30.0,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Fanconi anaemia"
        },
        "expected_difference": false
      }
    },
    {
      "test_id": "test_45_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406370",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_46_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406422",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_47_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
        "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406468",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_48_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406520",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_49_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406568",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_50_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406609",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_51_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406653",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_52_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406698",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_53_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406746",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_54_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406792",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_55_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406831",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_56_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406874",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_57_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406917",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_58_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.406962",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_59_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407007",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_LOH": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_60_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407045",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_61_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407095",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: High vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_62_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407142",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: High vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_63_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407182",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_64_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407220",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_65_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407269",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_66_tp53_terminology",
      "input_data": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with mutated TP53"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407309",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_67_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 200,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407358",
      "significance": "critical",
      "clinical_impact_score": 200,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_68_tp53_terminology",
      "input_data": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407402",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 10,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_69_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_TP53",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 200,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407449",
      "significance": "critical",
      "clinical_impact_score": 200,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_70_tp53_terminology",
      "input_data": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407492",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_71_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407538",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_72_tp53_terminology",
      "input_data": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407585",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 20,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_73_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407631",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_74_tp53_terminology",
      "input_data": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "tp53_terminology",
      "timestamp": "2025-06-06T22:51:57.407675",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 25,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_75_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS, unclassifiable",
      "icc_classification": "MDS, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_NOS",
      "icc_disease_type": "MDS_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 40,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407724",
      "significance": "medium",
      "clinical_impact_score": 40,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_76_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with low blasts and SF3B1",
      "icc_classification": "MDS with mutated SF3B1",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_SF3B1",
      "icc_disease_type": "MDS_SF3B1",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407770",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_77_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with low blasts and isolated 5q-",
      "icc_classification": "MDS with del(5q)",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "del(5q) detected => MDS with low blasts and isolated 5q-",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and isolated 5q- (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "del(5q) detected => MDS with del(5q)",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with del(5q) (ICC 2022)"
      ],
      "who_disease_type": "MDS_5Q",
      "icc_disease_type": "MDS_5Q",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and isolated 5q-",
        "icc_classification": "MDS with del(5q)",
        "who_category": "MDS_5Q",
        "icc_category": "MDS_5Q",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407815",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_78_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with low blasts",
      "icc_classification": "MDS, NOS with multilineage dysplasia",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "Multiple dysplastic lineages => MDS with low blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: 2",
        "Multilineage dysplasia => MDS, NOS with multilineage dysplasia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS with multilineage dysplasia (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_DYSPLASIA",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts",
        "icc_classification": "MDS, NOS with multilineage dysplasia",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_DYSPLASIA",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407862",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_79_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, unclassifiable",
      "icc_classification": "MDS, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: True",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_NOS",
      "icc_disease_type": "MDS_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 40,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407905",
      "significance": "medium",
      "clinical_impact_score": 40,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_80_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS, hypoplastic",
      "icc_classification": "MDS, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 4, fibrotic: False",
        "Hypoplasia detected => MDS, hypoplastic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, hypoplastic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 4",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 4",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, hypoplastic",
        "icc_classification": "MDS, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407945",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 4,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_81_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.407987",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_82_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408026",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_83_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408177",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_84_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408260",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_85_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408317",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_86_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408365",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_87_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408409",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_88_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408453",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_89_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408494",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_90_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408535",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_91_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408577",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_92_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408618",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_93_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408656",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_94_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408696",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_95_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408737",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_96_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408784",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_97_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: True",
        "5-9% blasts => MDS with increased blasts 1",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408867",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_98_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408915",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_99_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.408964",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_100_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409176",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_101_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409284",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_102_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409350",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_103_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409419",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_104_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 10, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 10",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409470",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 10,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_105_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409515",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_106_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409567",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_107_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409622",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_108_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409667",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_109_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409714",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_110_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409758",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_111_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409804",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_112_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409856",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_113_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409908",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_114_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.409985",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_115_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410030",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_116_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410074",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_117_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410117",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_118_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410161",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_119_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410206",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_120_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410248",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_121_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410286",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "fibrotic": true
      }
    },
    {
      "test_id": "test_122_mds_blast_ranges",
      "input_data": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "mds_blast_ranges",
      "timestamp": "2025-06-06T22:51:57.410322",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "hypoplasia": true
      }
    },
    {
      "test_id": "test_123_erythroid_handling",
      "input_data": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410364",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_124_erythroid_handling",
      "input_data": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410405",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_125_erythroid_handling",
      "input_data": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410445",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_126_erythroid_handling",
      "input_data": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6a",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410485",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6a",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_127_erythroid_handling",
      "input_data": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410526",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_128_erythroid_handling",
      "input_data": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410566",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_129_erythroid_handling",
      "input_data": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410605",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_130_erythroid_handling",
      "input_data": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      },
      "who_classification": "Acute Erythroid leukaemia",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "AML_differentiation: M6b",
        "Erythroid subtype => Acute Erythroid leukaemia",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute Erythroid leukaemia (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 30",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "erythroid_handling",
      "timestamp": "2025-06-06T22:51:57.410643",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 30,
        "AML_differentiation": "M6b",
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "qualifiers": {}
      }
    },
    {
      "test_id": "test_131_combination_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 15
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA",
        "CEBPA found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML, NOS, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS, therapy related",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T22:51:57.410698",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 15
      }
    },
    {
      "test_id": "test_132_combination_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "blasts_percentage": 20
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of Diamond-Blackfan anemia",
        "Qualifiers appended => AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 160,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Germline implications differ"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T22:51:57.410762",
      "significance": "critical",
      "clinical_impact_score": 160,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}",
        "Germline implications differ"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations",
        "Family screening recommendations differ",
        "Drug toxicity considerations differ"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {
          "predisposing_germline_variant": "Diamond-Blackfan anemia"
        },
        "blasts_percentage": 20
      }
    },
    {
      "test_id": "test_133_combination_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 12
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
        "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53, therapy related",
        "who_category": "MDS_TP53",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T22:51:57.410816",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "blasts_percentage": 12
      }
    },
    {
      "test_id": "test_134_combination_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25,
        "AML_differentiation": "M6a"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): ASXL1, SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6a",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "combination_scenarios",
      "timestamp": "2025-06-06T22:51:57.410862",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25,
        "AML_differentiation": "M6a"
      }
    },
    {
      "test_id": "test_135_edge_cases",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 0
      },
      "who_classification": "MDS, unclassifiable",
      "icc_classification": "MDS, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 0, fibrotic: False",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, unclassifiable (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 0",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 0",
        "number_of_dysplastic_lineages: None",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_NOS",
      "icc_disease_type": "MDS_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_category": "MDS_NOS",
        "icc_category": "MDS_NOS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "moderate_clinical_impact",
        "significance": "medium",
        "clinical_impact_score": 40,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": []
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T22:51:57.410906",
      "significance": "medium",
      "clinical_impact_score": 40,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 0
      }
    },
    {
      "test_id": "test_136_edge_cases",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 100
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 100",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 100",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T22:51:57.410944",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 100
      }
    },
    {
      "test_id": "test_137_edge_cases",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "RUNX1::RUNX1T1": true,
          "CBFB::MYH11": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T22:51:57.410983",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "RUNX1::RUNX1T1": true,
          "CBFB::MYH11": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 25
      }
    },
    {
      "test_id": "test_138_edge_cases",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true,
          "SF3B1": true,
          "SRSF2": true,
          "U2AF1": true,
          "EZH2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 8
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T22:51:57.411030",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true,
          "SF3B1": true,
          "SRSF2": true,
          "U2AF1": true,
          "EZH2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "blasts_percentage": 8
      }
    },
    {
      "test_id": "test_139_edge_cases",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true,
          "1_x_TP53_mutation_del_17p": true,
          "1_x_TP53_mutation_LOH": true,
          "1_x_TP53_mutation_50_percent_vaf": true,
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "qualifiers": {},
        "blasts_percentage": 15
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'2_x_TP53_mutations': True, '1_x_TP53_mutation_del_17p': True, '1_x_TP53_mutation_LOH': True, '1_x_TP53_mutation_50_percent_vaf': True, '1_x_TP53_mutation_10_percent_vaf': True}",
        "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_TP53",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_TP53",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "edge_cases",
      "timestamp": "2025-06-06T22:51:57.411081",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true,
          "1_x_TP53_mutation_del_17p": true,
          "1_x_TP53_mutation_LOH": true,
          "1_x_TP53_mutation_50_percent_vaf": true,
          "1_x_TP53_mutation_10_percent_vaf": true
        },
        "qualifiers": {},
        "blasts_percentage": 15
      }
    },
    {
      "test_id": "test_140_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {},
        "scenario_name": "elderly_mds_with_tp53",
        "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
        "blasts_percentage": 12,
        "age": 75
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_TP53",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411133",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: High vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {},
        "scenario_name": "elderly_mds_with_tp53",
        "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
        "blasts_percentage": 12,
        "age": 75
      }
    },
    {
      "test_id": "test_141_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411171",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      }
    },
    {
      "test_id": "test_142_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, RUNX1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411212",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      }
    },
    {
      "test_id": "test_143_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411252",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      }
    },
    {
      "test_id": "test_144_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
      "icc_classification": "AML with mutated TP53, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411309",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      }
    },
    {
      "test_id": "test_145_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "mds_sf3b1_ring_sideroblasts",
        "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
        "blasts_percentage": 3,
        "number_of_dysplastic_lineages": 1
      },
      "who_classification": "MDS with low blasts and SF3B1",
      "icc_classification": "MDS with mutated SF3B1",
      "who_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 3, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 3",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_SF3B1",
      "icc_disease_type": "MDS_SF3B1",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411353",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "mds_sf3b1_ring_sideroblasts",
        "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
        "blasts_percentage": 3,
        "number_of_dysplastic_lineages": 1
      }
    },
    {
      "test_id": "test_146_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "hypoplastic_mds",
        "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
        "blasts_percentage": 8,
        "hypoplasia": true,
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411395",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "hypoplastic_mds",
        "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
        "blasts_percentage": 8,
        "hypoplasia": true,
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_147_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "fibrotic_mds",
        "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
        "blasts_percentage": 15,
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T22:51:57.411447",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "fibrotic_mds",
        "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
        "blasts_percentage": 15,
        "fibrotic": true
      }
    },
    {
      "test_id": "test_148_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411492",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "cebpa_bzip"
      }
    },
    {
      "test_id": "test_149_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411529",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "pediatric",
        "genetic_context": "npm1_flt3"
      }
    },
    {
      "test_id": "test_150_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411588",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "runx1_germline"
      }
    },
    {
      "test_id": "test_151_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
      "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411647",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "age": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "pediatric",
        "genetic_context": "ddx41_germline"
      }
    },
    {
      "test_id": "test_152_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "AML with CEBPA mutation",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA with blasts >=20 => AML with CEBPA mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with CEBPA mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411688",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "cebpa_bzip"
      }
    },
    {
      "test_id": "test_153_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411725",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "young_adult",
        "genetic_context": "npm1_flt3"
      }
    },
    {
      "test_id": "test_154_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
      "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411778",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "runx1_germline"
      }
    },
    {
      "test_id": "test_155_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
      "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411834",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 20,
        "age": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "young_adult",
        "genetic_context": "ddx41_germline"
      }
    },
    {
      "test_id": "test_156_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA found but blasts <20 => not AML by this route",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 190,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411889",
      "significance": "critical",
      "clinical_impact_score": 190,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "cebpa_bzip"
      }
    },
    {
      "test_id": "test_157_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.411927",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "middle_aged",
        "genetic_context": "npm1_flt3"
      }
    },
    {
      "test_id": "test_158_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412019",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "runx1_germline"
      }
    },
    {
      "test_id": "test_159_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
      "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412085",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 18,
        "age": 55,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "middle_aged",
        "genetic_context": "ddx41_germline"
      }
    },
    {
      "test_id": "test_160_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "cebpa_bzip"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with in-frame bZIP mutated CEBPA",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA, bZIP",
        "CEBPA found but blasts <20 => not AML by this route",
        "bZIP found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA, bZIP",
        "bZIP => AML with in-frame bZIP mutated CEBPA",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 190,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412159",
      "significance": "critical",
      "clinical_impact_score": 190,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'cebpa'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA": true,
          "bZIP": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "cebpa_bzip"
      }
    },
    {
      "test_id": "test_161_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "npm1_flt3"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412220",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "age_group": "elderly",
        "genetic_context": "npm1_flt3"
      }
    },
    {
      "test_id": "test_162_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "runx1_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
      "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline RUNX1 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline RUNX1 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 100,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412290",
      "significance": "critical",
      "clinical_impact_score": 100,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline RUNX1 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "runx1_germline"
      }
    },
    {
      "test_id": "test_163_age_dependent_differences",
      "input_data": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "ddx41_germline"
      },
      "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
      "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected germline predisposition => associated with germline DDX41 mutation",
        "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
        "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "Qualifier => in the setting of germline DDX41 mutation",
        "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "age_dependent_differences",
      "timestamp": "2025-06-06T22:51:57.412436",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 15,
        "age": 78,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "predisposing_germline_variant": "germline DDX41 mutation"
        },
        "age_group": "elderly",
        "genetic_context": "ddx41_germline"
      }
    },
    {
      "test_id": "test_164_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 22,
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true,
          "del_17p": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "complex_karyotype_tp53",
        "scenario_description": "Complex karyotype with TP53 mutation"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype, del_17p => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412517",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 22,
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true,
          "del_17p": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "complex_karyotype_tp53",
        "scenario_description": "Complex karyotype with TP53 mutation"
      }
    },
    {
      "test_id": "test_165_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 18,
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del5q_syndrome_progression",
        "scenario_description": "del(5q) syndrome with blast progression"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412619",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 18,
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del5q_syndrome_progression",
        "scenario_description": "del(5q) syndrome with blast progression"
      }
    },
    {
      "test_id": "test_166_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 25,
        "MDS_related_cytogenetics": {
          "-7": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "monosomy7_childhood",
        "scenario_description": "Monosomy 7 in young patient",
        "age": 8
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412696",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "MDS_related_cytogenetics": {
          "-7": true
        },
        "MDS_related_mutation": {},
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "monosomy7_childhood",
        "scenario_description": "Monosomy 7 in young patient",
        "age": 8
      }
    },
    {
      "test_id": "test_167_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 45,
        "MDS_related_cytogenetics": {
          "inv3_t33": true
        },
        "MDS_related_mutation": {
          "EVI1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "inv3_evi1_aml",
        "scenario_description": "inv(3) with EVI1 rearrangement"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): EVI1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412749",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 45,
        "MDS_related_cytogenetics": {
          "inv3_t33": true
        },
        "MDS_related_mutation": {
          "EVI1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "inv3_evi1_aml",
        "scenario_description": "inv(3) with EVI1 rearrangement"
      }
    },
    {
      "test_id": "test_168_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 8,
        "MDS_related_cytogenetics": {
          "del_7q": true
        },
        "MDS_related_mutation": {
          "RUNX1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del7q_mds",
        "scenario_description": "del(7q) in MDS"
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412800",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 8,
        "MDS_related_cytogenetics": {
          "del_7q": true
        },
        "MDS_related_mutation": {
          "RUNX1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "del7q_mds",
        "scenario_description": "del(7q) in MDS"
      }
    },
    {
      "test_id": "test_169_complex_cytogenetics",
      "input_data": {
        "blasts_percentage": 28,
        "MDS_related_cytogenetics": {},
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true,
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "normal_karyotype_multiple_mutations",
        "scenario_description": "Normal karyotype with multiple mutations"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): DNMT3A, TET2, ASXL1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 28",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "complex_cytogenetics",
      "timestamp": "2025-06-06T22:51:57.412848",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 28,
        "MDS_related_cytogenetics": {},
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true,
          "ASXL1": true
        },
        "Biallelic_TP53_mutation": {},
        "AML_defining_recurrent_genetic_abnormalities": {},
        "qualifiers": {},
        "scenario_name": "normal_karyotype_multiple_mutations",
        "scenario_description": "Normal karyotype with multiple mutations"
      }
    },
    {
      "test_id": "test_170_comutation_patterns",
      "input_data": {
        "blasts_percentage": 75,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "dnmt3a_npm1_flt3",
        "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 75",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1, FLT3_ITD",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.412888",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 75,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true,
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "dnmt3a_npm1_flt3",
        "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
      }
    },
    {
      "test_id": "test_171_comutation_patterns",
      "input_data": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "tet2_sf3b1_mds",
        "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 5, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 5",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 5",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.412933",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 5,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "tet2_sf3b1_mds",
        "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
      }
    },
    {
      "test_id": "test_172_comutation_patterns",
      "input_data": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.412987",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "asxl1_runx1_poor_risk",
        "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
      }
    },
    {
      "test_id": "test_173_comutation_patterns",
      "input_data": {
        "blasts_percentage": 35,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {},
        "pattern_name": "tp53_complex_karyotype",
        "pattern_description": "TP53 mutation with complex karyotype"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with mutated TP53",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated TP53 (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "UNCLASSIFIABLE",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.413037",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 35,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "2_x_TP53_mutations": true
        },
        "qualifiers": {},
        "pattern_name": "tp53_complex_karyotype",
        "pattern_description": "TP53 mutation with complex karyotype"
      }
    },
    {
      "test_id": "test_174_comutation_patterns",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SRSF2": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "srsf2_tet2_cmml_like",
        "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.413195",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SRSF2": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "srsf2_tet2_cmml_like",
        "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
      }
    },
    {
      "test_id": "test_175_comutation_patterns",
      "input_data": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "U2AF1": true,
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "pattern_name": "u2af1_dnmt3a_secondary",
        "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
      },
      "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
      "icc_classification": "MDS with excess blasts, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 9, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 9",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 9",
        "5-9% blasts => MDS with excess blasts",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => MDS with excess blasts, therapy related",
        "Final classification => MDS with excess blasts, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
        "icc_classification": "MDS with excess blasts, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.413280",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 9,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "U2AF1": true,
          "DNMT3A": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "pattern_name": "u2af1_dnmt3a_secondary",
        "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
      }
    },
    {
      "test_id": "test_176_comutation_patterns",
      "input_data": {
        "blasts_percentage": 14,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "EZH2": true,
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "ezh2_asxl1_high_risk",
        "pattern_description": "EZH2 + ASXL1 high-risk combination"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 14, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 14",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "comutation_patterns",
      "timestamp": "2025-06-06T22:51:57.413353",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 14,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "EZH2": true,
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "pattern_name": "ezh2_asxl1_high_risk",
        "pattern_description": "EZH2 + ASXL1 high-risk combination"
      }
    },
    {
      "test_id": "test_177_therapy_evolution",
      "input_data": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "NRAS": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Previous MDS"
        },
        "scenario_name": "mds_to_aml_progression",
        "scenario_description": "MDS progression to AML with acquired mutations"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, NRAS => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T22:51:57.413404",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 25,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "NRAS": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Previous MDS"
        },
        "scenario_name": "mds_to_aml_progression",
        "scenario_description": "MDS progression to AML with acquired mutations"
      }
    },
    {
      "test_id": "test_178_therapy_evolution",
      "input_data": {
        "blasts_percentage": 45,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "post_chemo_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
      },
      "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
      "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
        "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T22:51:57.413468",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 45,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "post_chemo_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
      }
    },
    {
      "test_id": "test_179_therapy_evolution",
      "input_data": {
        "blasts_percentage": 60,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "NPM1": true,
          "TP53": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "relapsed_aml_new_mutations",
        "scenario_description": "Relapsed AML with additional mutations"
      },
      "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
      "icc_classification": "AML with myelodysplasia related gene mutation, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 60",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): NPM1, TP53 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
        "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 60",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related gene mutation, therapy related",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T22:51:57.413527",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "blasts_percentage": 60,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "NPM1": true,
          "TP53": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "relapsed_aml_new_mutations",
        "scenario_description": "Relapsed AML with additional mutations"
      }
    },
    {
      "test_id": "test_180_therapy_evolution",
      "input_data": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true,
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "scenario_name": "post_radiation_mds",
        "scenario_description": "Radiation-induced MDS with del(5q)"
      },
      "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
        "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic therapy",
        "Final classification => MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "Detected ICC therapy => therapy related: Ionising radiation",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T22:51:57.413603",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true,
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Ionising radiation"
        },
        "scenario_name": "post_radiation_mds",
        "scenario_description": "Radiation-induced MDS with del(5q)"
      }
    },
    {
      "test_id": "test_181_therapy_evolution",
      "input_data": {
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "scenario_name": "immune_therapy_related",
        "scenario_description": "Post-immunotherapy myeloid neoplasm"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "Detected ICC therapy => therapy related: Immune interventions",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "therapy_evolution",
      "timestamp": "2025-06-06T22:51:57.413664",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_cytotoxic_therapy": "Immune interventions"
        },
        "scenario_name": "immune_therapy_related",
        "scenario_description": "Post-immunotherapy myeloid neoplasm"
      }
    },
    {
      "test_id": "test_182_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_15_with_cebpa_bzip",
        "description": "15% blasts with CEBPA bZIP mutation - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413718",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_15_with_cebpa_bzip",
        "description": "15% blasts with CEBPA bZIP mutation - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_183_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_12_with_npm1",
        "description": "12% blasts with NPM1 mutation - borderline case",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413772",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_12_with_npm1",
        "description": "12% blasts with NPM1 mutation - borderline case",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_184_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_18_with_runx1_runx1t1",
        "description": "18% blasts with RUNX1-RUNX1T1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1_RUNX1T1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1_RUNX1T1",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1_RUNX1T1",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413831",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_18_with_runx1_runx1t1",
        "description": "18% blasts with RUNX1-RUNX1T1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1_RUNX1T1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_185_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_16_with_inv16",
        "description": "16% blasts with inv(16) - core binding factor",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CBFB_MYH11": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CBFB_MYH11",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 16, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 16",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CBFB_MYH11",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413881",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_16_with_inv16",
        "description": "16% blasts with inv(16) - core binding factor",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 16,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CBFB_MYH11": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_186_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_19_with_sf3b1_asxl1",
        "description": "19% blasts with SF3B1 and ASXL1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "MDS_related_mutation": {
          "SF3B1": true,
          "ASXL1": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413946",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_19_with_sf3b1_asxl1",
        "description": "19% blasts with SF3B1 and ASXL1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "MDS_related_mutation": {
          "SF3B1": true,
          "ASXL1": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_187_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_21_with_tet2_dnmt3a",
        "description": "21% blasts with TET2 and DNMT3A mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "MDS_related_mutation": {
          "TET2": true,
          "DNMT3A": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): TET2, DNMT3A => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.413990",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "blast_21_with_tet2_dnmt3a",
        "description": "21% blasts with TET2 and DNMT3A mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "MDS_related_mutation": {
          "TET2": true,
          "DNMT3A": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_188_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_18_with_srsf2_u2af1",
        "description": "18% blasts with SRSF2 and U2AF1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "SRSF2": true,
          "U2AF1": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414041",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_18_with_srsf2_u2af1",
        "description": "18% blasts with SRSF2 and U2AF1 mutations",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "SRSF2": true,
          "U2AF1": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_189_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "tr_blast_15_with_tp53",
        "description": "Therapy-related case with 15% blasts and TP53 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_TP53",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414093",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: High vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "tr_blast_15_with_tp53",
        "description": "Therapy-related case with 15% blasts and TP53 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_190_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "tr_blast_22_complex_karyotype",
        "description": "Therapy-related case with 22% blasts and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "complex_karyotype": true,
        "therapy_qualifier": "Ionising radiation",
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414169",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "tr_blast_22_complex_karyotype",
        "description": "Therapy-related case with 22% blasts and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "complex_karyotype": true,
        "therapy_qualifier": "Ionising radiation",
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_191_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "erythroid_blast_18_dysplastic",
        "description": "18% blasts with erythroid predominance and dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_differentiation": "M6",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414218",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "erythroid_blast_18_dysplastic",
        "description": "18% blasts with erythroid predominance and dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_differentiation": "M6",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_192_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "erythroid_blast_25_with_sf3b1",
        "description": "25% blasts with erythroid features and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 25,
        "AML_differentiation": "M6",
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "AML_differentiation: M6",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 25",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414261",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "erythroid_blast_25_with_sf3b1",
        "description": "25% blasts with erythroid features and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 25,
        "AML_differentiation": "M6",
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_193_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_19_npm1_with_dysplasia",
        "description": "19% blasts with NPM1 mutation but significant dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414314",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_19_npm1_with_dysplasia",
        "description": "19% blasts with NPM1 mutation but significant dysplasia",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "DNMT3A": true,
          "TET2": true
        },
        "dysplastic_lineages": 3,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_194_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_17_flt3_with_mds_changes",
        "description": "17% blasts with FLT3-ITD and MDS-related changes",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 17,
        "AML_defining_recurrent_genetic_abnormalities": {
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "ASXL1": true,
          "SRSF2": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 17",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: FLT3_ITD",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 17, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 17",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => FLT3_ITD",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414366",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_17_flt3_with_mds_changes",
        "description": "17% blasts with FLT3-ITD and MDS-related changes",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 17,
        "AML_defining_recurrent_genetic_abnormalities": {
          "FLT3_ITD": true
        },
        "MDS_related_mutation": {
          "ASXL1": true,
          "SRSF2": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_195_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "blast_21_cebpa_with_complex_karyotype",
        "description": "21% blasts with CEBPA mutation and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "complex_karyotype": true,
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation",
      "icc_classification": "AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 21",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_NOS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_NOS",
        "are_equivalent": true,
        "category_match": false,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414410",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "blast_21_cebpa_with_complex_karyotype",
        "description": "21% blasts with CEBPA mutation and complex karyotype",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 21,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "complex_karyotype": true,
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_196_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "previous_mds_blast_18",
        "description": "18% blasts in patient with previous MDS diagnosis",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414458",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "previous_mds_blast_18",
        "description": "18% blasts in patient with previous MDS diagnosis",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "MDS_related_mutation": {
          "TET2": true,
          "SF3B1": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_197_aml_vs_mds_borderline",
      "input_data": {
        "test_name": "previous_mds_blast_22_with_new_mutation",
        "description": "22% blasts with previous MDS and new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "TET2": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "MDS-related mutation(s): TET2 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 22",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "aml_vs_mds_borderline",
      "timestamp": "2025-06-06T22:51:57.414503",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "previous_mds_blast_22_with_new_mutation",
        "description": "22% blasts with previous MDS and new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 22,
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "MDS_related_mutation": {
          "TET2": true
        },
        "previous_mds_mpn": "Previous MDS",
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_198_disease_type_disagreement",
      "input_data": {
        "test_name": "who_aml_icc_mds_blast_20_with_dysplasia",
        "description": "20% blasts with extensive dysplasia - WHO may favor AML, ICC may favor MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "dysplastic_lineages": 3,
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true,
          "SRSF2": true
        },
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): ASXL1, TET2, SRSF2 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414554",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "who_aml_icc_mds_blast_20_with_dysplasia",
        "description": "20% blasts with extensive dysplasia - WHO may favor AML, ICC may favor MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "dysplastic_lineages": 3,
        "MDS_related_mutation": {
          "ASXL1": true,
          "TET2": true,
          "SRSF2": true
        },
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_199_disease_type_disagreement",
      "input_data": {
        "test_name": "blast_20_with_ring_sideroblasts",
        "description": "20% blasts with >15% ring sideroblasts and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular",
        "ring_sideroblasts_percent": 25
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 20",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414615",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "test_name": "blast_20_with_ring_sideroblasts",
        "description": "20% blasts with >15% ring sideroblasts and SF3B1 mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 20,
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular",
        "ring_sideroblasts_percent": 25
      }
    },
    {
      "test_id": "test_200_disease_type_disagreement",
      "input_data": {
        "test_name": "who_mds_icc_aml_blast_15_cebpa",
        "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: CEBPA_bZIP",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => CEBPA_bZIP",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414664",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "who_mds_icc_aml_blast_15_cebpa",
        "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "AML_defining_recurrent_genetic_abnormalities": {
          "CEBPA_bZIP": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_201_disease_type_disagreement",
      "input_data": {
        "test_name": "blast_12_with_bcr_abl1",
        "description": "12% blasts with BCR::ABL1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: BCR::ABL1",
        "BCR::ABL1 found but blasts <20 => not AML by this route",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 12, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => BCR::ABL1",
        "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_GENETIC",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 160,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414719",
      "significance": "critical",
      "clinical_impact_score": 160,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [
        "Molecular vs flow cytometry MRD monitoring",
        "Different sensitivity and specificity"
      ],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_12_with_bcr_abl1",
        "description": "12% blasts with BCR::ABL1 fusion",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 12,
        "AML_defining_recurrent_genetic_abnormalities": {
          "BCR::ABL1": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_202_disease_type_disagreement",
      "input_data": {
        "test_name": "blast_18_with_kmt2a_rearrangement",
        "description": "18% blasts with KMT2A rearrangement",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "KMT2A_rearranged": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: KMT2A_rearranged",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 18, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 18",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => KMT2A_rearranged",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414766",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "blast_18_with_kmt2a_rearrangement",
        "description": "18% blasts with KMT2A rearrangement",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 18,
        "AML_defining_recurrent_genetic_abnormalities": {
          "KMT2A_rearranged": true
        },
        "dysplastic_lineages": 0,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_203_disease_type_disagreement",
      "input_data": {
        "test_name": "tr_blast_15_immune_intervention",
        "description": "15% blasts after immune intervention therapy",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "therapy_qualifier": "Immune interventions (ICC)",
        "MDS_related_mutation": {
          "TP53": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_BLASTS",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414817",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "tr_blast_15_immune_intervention",
        "description": "15% blasts after immune intervention therapy",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 15,
        "therapy_qualifier": "Immune interventions (ICC)",
        "MDS_related_mutation": {
          "TP53": true
        },
        "dysplastic_lineages": 2,
        "bone_marrow_cellularity": "Hypercellular"
      }
    },
    {
      "test_id": "test_204_disease_type_disagreement",
      "input_data": {
        "test_name": "tr_blast_19_with_aml_mutation",
        "description": "19% blasts after chemotherapy with new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      },
      "who_classification": "MDS with increased blasts 2",
      "icc_classification": "MDS/AML, NOS",
      "who_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1_mutation",
        "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 19, fibrotic: False",
        "10-19% blasts => MDS with increased blasts 2",
        "Current classification: MDS with increased blasts 2",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 2 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 19",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1_mutation",
        "No single ICC AML-def abnormality triggered classification.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "No MDS-related cytogenetics triggered classification.",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML, NOS (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_AML_HYBRID",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "disease_type_disagreement",
      "timestamp": "2025-06-06T22:51:57.414868",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "test_name": "tr_blast_19_with_aml_mutation",
        "description": "19% blasts after chemotherapy with new AML-defining mutation",
        "expected_difference": true,
        "significance": "high",
        "blasts_percentage": 19,
        "therapy_qualifier": "Cytotoxic chemotherapy",
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1_mutation": true
        },
        "dysplastic_lineages": 1,
        "bone_marrow_cellularity": "Hypercellular"
      }
    }
  ],
  "timestamp": "2025-06-06T22:51:57.429683",
  "total_tests": 204
}